A Radical Shift: Heart and Kidney Disease Are Now Viewed as One Syndrome

For years, we have seen medicine separately address heart disease, diabetes, and kidney disease as individual wars. But a new initiative from the American Heart Association is dissolving those walls, saying they are manifestations of the same condition: Cardiovascular–Kidney– Metabolic (CKM) Syndrome.

This revolution can turn care around for millions. Why? Because obesity, insulin resistance, and high blood pressure tend to hit at the same time, quietly impairing blood vessels, kidneys, and the heart years before a heart attack or kidney disease. Rather than responding too late, the new system encourages physicians to respond early— screening young adults for risk, considering waist circumference in addition to blood sugar, and incorporating social determinants such as diet, stress, and access to care in the community.

The model establishes five stages, from risk-free prevention (Stage 0) through full-blown disease (Stage 4). Those with excess belly fat or prediabetes are identified as early as Stage 1, so that intervention occurs before the onset of the first warning signs.

Treatment also evolves. The guidance points out medications that cross diseases: SGLT-2 inhibitors to guard the heart and kidneys, GLP-1 receptor agonists to aid in weight and blood sugar, and lifestyle changes that lower all three risks simultaneously. Most importantly, it demands coordinated, team-delivered care—so patients aren't shuffled among specialists, but guided by a single, integrative plan.

The bottom line: CKM Syndrome transforms the way we view chronic illness. Rather than isolated issues, it's a single interrelated crisis—and one that can be slowed or prevented if addressed early and as a team.

Might this "one-disease" strategy shift the way your doctor works with you to manage your health? Learn more here.